Synopsis: Alembic Pharmaceuticals Limited’s partner NATCO Pharma has received USFDA tentative approval for Olaparib Tablets (100 mg and 150 mg), a generic version of AstraZeneca’s Lynparza. The product addresses a U.S. market estimated at USD 1.4 billion, with Alembic set to distribute the drug in the United States.
Shares of Alembic Pharmaceuticals Limited are likely to remain in focus after the company announced that its partner NATCO Pharma Limited has received tentative approval from the U.S. Food and Drug Administration (USFDA) for Olaparib Tablets, 100 mg and 150 mg, expanding its oncology pipeline in the U.S. market.
Alembic Pharmaceuticals Limited has a total market capitalization of approximately Rs. 16377 crore. The company’s shares were trading at Rs. 834.55 apiece on the stock exchange, up by 1.18 percent. The stock has gained 1.83 percent over the last five trading sessions and gained 6.89 percent over the last month. The stock touched a 52-week high of Rs. 1038 and a 52-week low of Rs 636.
According to the company’s exchange filing, NATCO Pharma Limited has received USFDA tentative approval for its Abbreviated New Drug Application (ANDA) for Olaparib Tablets, 100 mg and 150 mg. The product is therapeutically equivalent to Lynparza, developed by AstraZeneca Pharmaceuticals LP, and is indicated for approved oncology treatments.
Under the partnership arrangement, NATCO Pharma will manufacture the product, while Alembic Pharmaceuticals will be responsible for its distribution in the United States. However, the company stated that the Paragraph IV patent litigation remains ongoing, and commercial launch will be subject to the resolution of the legal proceedings and receipt of final approval.
According to IQVIA, Olaparib Tablets recorded an estimated U.S. market size of approximately USD 1.4 billion for the twelve months ended March 2026, highlighting the significant commercial opportunity for the product upon launch.
With this development, Alembic Pharmaceuticals now has a cumulative total of 244 ANDA approvals from the USFDA, comprising 224 final approvals and 20 tentative approvals, reflecting the company’s continued focus on expanding its global generic pharmaceuticals portfolio.
The U.S. generics market remains one of the largest pharmaceutical markets globally, with oncology drugs representing a high-growth segment due to increasing cancer incidence and rising demand for cost-effective treatment alternatives. Regulatory approvals for complex generic drugs continue to create long-term growth opportunities for Indian pharmaceutical manufacturers.
For investors, the tentative approval strengthens Alembic’s U.S. product pipeline and reinforces its partnership with NATCO Pharma in the oncology segment. While commercialisation remains dependent on patent litigation and final regulatory approval, the sizeable addressable market provides significant long-term revenue potential.
Incorporated in 1907, Alembic Pharmaceuticals Limited is a research-driven, vertically integrated pharmaceutical company engaged in the development, manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company operates three R&D centres and five manufacturing facilities, with regulatory approvals from several global authorities, including the USFDA. It is one of India’s leading branded generic pharmaceutical companies with a strong presence across domestic and international markets.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses arising from decisions based on this article. Please consult your investment advisor before investing.
